Phuturdex › Diseases › Tick-borne disease
Drugs in development · updated 9 November 2026
Tick-borne disease: drugs in development
What it is
Tick-borne diseases, which afflict humans and other animals, are caused by infectious agents transmitted by tick bites. They are caused by infection with a variety of pathogens, including rickettsia and other types of bacteria, viruses, and protozoa. The economic impact of tick-borne diseases is considered to be substantial in humans, and tick-borne diseases are estimated to affect ~80 % of cattle worldwide. Most of these pathogens require passage through vertebrate hosts as part of their life cycle. Tick-borne infections in humans, farm animals, and companion animals are primarily associated with wildlife animal reservoirs.
Description not checked by Phuturdex: excerpt from the introduction of the article “Tick-borne disease” on English Wikipedia, en.wikipedia.org · version of 9 November 2026 · licence CC BY-SA 4.0.
As of 9 November 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for tick-borne disease. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 9 November 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| VLA15 | III | 2 | NCT07500506 |
| Favipiravir | II | 1 | NCT06860334 |
| MRNA-1982 | II | 1 | NCT07561294 |
| TP-05 | II | 1 | NCT07562087 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DexamethasoneDexametasone, Dextenza | III | 1 | NCT07584525 |
| Cromolyn SodiumCromoglycate, Sodium Cromoglicate | II | 1 | NCT07526558 |
| KetotifenAcuvue Theravision With Ketotifen®, Children'S Alaway® | II | 1 | NCT07526558 |
| RibavirinRibavin, Rebetol® | II | 1 | NCT06860334 |
| TafenoquineKrintafel®, Arakoda® | II | 1 | NCT06207370 |
| CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container® | Early I | 1 | NCT06611111 |
Sorted by most advanced phase and number of active trials.
All 10 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
Broader categories
- Infection 877 drugs
- Immune System Diseases 1,556 drugs
- Vector-borne disease 80 drugs
- Wounds and Injuries 195 drugs
- Bites and stings 19 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D017282 “Tick-Borne Diseases”.